Tianjin TEDA Biomedical Engineering Company Limited (HKG:8189)

HKG:8189 Ratios and Metrics

Market cap in millions HKD. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr 1, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	619	651	616	169	379	322
Market Cap Growth	-41.39%	5.71%	265.17%	-55.50%	17.65%	73.47%
Enterprise Value	698	575	945	219	415	295
Last Close Price	0.29	0.30	0.33	0.09	0.20	0.17
PS Ratio	1.06	1.12	1.50	0.39	0.83	0.55
PB Ratio	203.54	214.07	20.34	2.37	4.13	2.38
P/TBV Ratio	45.49	47.85	26.12	3.06	5.78	2.60
EV/Sales Ratio	1.20	0.99	2.30	0.50	0.91	0.51
EV/EBITDA Ratio	143.68	118.28	-	-	-	-
Debt / Equity Ratio	40.17	40.17	5.70	1.33	1.26	0.82
Debt / EBITDA Ratio	25.12	25.12	-	-	-	-
Net Debt / Equity Ratio	29.48	29.48	4.81	1.24	1.18	0.57
Net Debt / EBITDA Ratio	18.43	18.43	-6.39	-7.64	-6.44	-4.41
Net Debt / FCF Ratio	-	-	-4.74	-5.11	-4.41	-1.83
Asset Turnover	1.75	1.75	1.21	1.24	1.18	1.29
Inventory Turnover	7.06	7.06	4.45	4.58	5.21	5.16
Quick Ratio	0.18	0.18	0.14	0.11	0.21	0.35
Current Ratio	0.75	0.75	0.84	0.88	0.89	1.09
Return on Equity (ROE)	-728.50%	-728.50%	-81.67%	-15.05%	-24.59%	-33.73%
Return on Assets (ROA)	-0.55%	-0.55%	-5.58%	-3.77%	-4.46%	-3.10%
Return on Invested Capital (ROIC)	-3.13%	-2.10%	-18.34%	-12.05%	-13.96%	-10.58%
Return on Capital Employed (ROCE)	-20.00%	-20.00%	-53.10%	-22.40%	-20.50%	-11.80%
Earnings Yield	-16.33%	-15.53%	-4.81%	-13.17%	-8.19%	-16.11%
FCF Yield	-	-	-4.98%	-10.21%	-6.45%	-13.07%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.